Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 3 (9), e372

Antidepressants and Violence: Problems at the Interface of Medicine and Law

Affiliations
Review

Antidepressants and Violence: Problems at the Interface of Medicine and Law

David Healy et al. PLoS Med.

Abstract

David Healy and colleagues review several sources of data which suggest an association in a small number of cases between antidepressant treatment and aggression and violence.

Conflict of interest statement

Competing Interests: DH has been an expert witness in nine cases involving antidepressants and suicide or violence. He has given views that the antidepressant was unlikely to be involved in approximately 100 further cases. He has been a consultant or speaker for most of the major pharmaceutical companies. AH has been an expert witness in 12 cases involving antidepressants and suicide or violence. He has given views that the antidepressant was unlikely to be involved in approximately two further cases. DBM has been an expert witness in six cases involving antidepressants and suicide or violence. He has given views that the antidepressant was unlikely to be involved in approximately 20 further cases. He has received research support from Roche and Eli Lilly, and has spoken for most of the major pharmaceutical companies.

Similar articles

See all similar articles

Cited by 19 PubMed Central articles

See all "Cited by" articles

References

    1. Healy D. New York: New York University Press; 2004. Let them eat Prozac; pp. 124–148.
    1. Pfizer Canada. Stronger warning for SSRIs and other newer antidepressants regarding the potential for behavioural and emotional changes, including risk of self-harm. 2004 May 26. Available: http://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/2004/zoloft_2_hpc-cps_e.html. Accessed 21 July 2006.
    1. Pfizer. Zoloft prescribing information. 2005 February. Available: http://www.fda.gov/cder/foi/label/2005/019839s053S054lbl.pdf. Accessed 21 July 2006.
    1. Medicines and Healthcare Products Regulatory Agency. Report of the CSM expert working group on the safety of selective serotonin reuptake inhibitors. 2004. Available: http://www.mhra.gov.uk/home/idcplg?IdcService=GET_FILE&dDocName=CON019472&RevisionSelectionMethod=LatestReleased. Accessed 21 July 2006.
    1. GlaxoSmithKline. Paroxetine adult suicidality analysis: Major depressive disorder and non-major depressive disorder—Appendix 2. 2006. Available: http://www.gsk.com/media/par_current_analysis.htm. Accessed 21 July 2006.

Substances

Feedback